Galmed Pharmaceuticals Ltd (GLMD) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Galmed Pharmaceuticals Ltd   (NASDAQ: GLMD)

Galmed Pharmaceuticals Ltd 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Galmed Pharmaceuticals Ltd in the fourth quarter 2025?
Galmed Pharmaceuticals Ltd achieved a return on average equity (ROE) of 7.75 % in its fourth quarter 2025, this is above GLMD's average return on equity of 6.92%.
Galmed Pharmaceuticals Ltd shareholder's equity over the 12 months ending in its fourth quarter 2025 are valued at $18 million

ROE fell compared to the third quarter 2025, despite the net income growth of % from the third quarter 2025.

Within the Major Pharmaceutical Preparations industry 19 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 117, from total ROE ranking in the third quarter 2025 at 180.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Equity Change -3.34 % 3.67 % 74.12 % 32.31 % -
Y / Y Net Income Change -56.25 % - - - -53.7 %
Net Income (TTM) in Millions 1 3 3 3 3
Return On Equity (TTM) 7.75 % 17.57 % 17.74 % 20.18 % 21.58 %
GLMD's Total Ranking # 117 # 180 # # #
Equity (TTM) in Millions 16 19 21 17 16
Seq. Equity Change -17.42 % -6.88 % 21.6 % 3.37 % -11.44 %
Seq. Net Income Change - - - - -

Back to GLMD Management Effectiveness >> GLMD's 5 Years Annual ROE >> Compare GLMD ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 20
Sector # 44
Overall # 117

Return On Equity Statistics
High Average Low
133.35 %
6.92 %
-153.07 %
(Dec 31 2022)   (Dec 31 2016)





GLMD Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 16 16 14 13 30
Y / Y Equity Change -3.34 % 17.64 % 3.4 % -55.99 % -30.93 %
Net Income in Millions 7 8 10 18 32
Y / Y Net Income Change -8 % -27.18 % -42.46 % -44.75 % -
Return On Equity 43.72 % 45.94 % 74.21 % 133.35 % 106.24 %

Back to GLMD Management Effectiveness >> GLMD's 5 Years Annual ROE >> Compare GLMD ROE to its Competitors




Annual Roe Comment
In 2025 ROE decreased compared to the previous year to 43.72 %, due to deterioration of net income.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
GLMD's' Return on Equity at Yahoo Finance
GLMD's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for GLMD's Competitors
Subscribers only: Roe for Galmed Pharmaceuticals Ltd 's Suppliers
Subscribers only: Return On Equity for GLMD's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE
Mimedx Group Inc   21.24 %
Universal Health Services Inc   21.19 %
Inspire Medical Systems inc   21.07 %
Astrazeneca Plc  21.00 %
Haemonetics Corporation  20.80 %
Sbc Medical Group Holdings Incorporated  20.79 %
Lantheus Holdings Inc   20.58 %
Electromed Inc   20.54 %
Teva Pharmaceutical Industries Limited  20.07 %
Harmony Biosciences Holdings inc   19.84 %
Pediatrix Medical Group Inc   19.58 %
United Therapeutics Corporation  19.30 %
Krystal Biotech Inc   18.69 %
Argenx Se  17.64 %
Kewaunee Scientific Corporation  17.52 %
Black Diamond Therapeutics Inc   17.46 %
Insulet Corporation  17.36 %
Ufp Technologies Inc   17.36 %
West Pharmaceutical Services Inc   16.68 %
Neurocrine Biosciences Inc   16.67 %
Ensign Group Inc  16.57 %
Ani Pharmaceuticals Inc  16.48 %
Genmab A  16.47 %
Strata Critical Medical Inc   16.46 %
Intuitive Surgical Inc   16.40 %
Cryoport inc   15.75 %
Lemaitre Vascular Inc   15.58 %
Option Care Health Inc   15.39 %
Sab Biotherapeutics Inc   15.17 %
Corcept Therapeutics Inc  15.11 %

Date modified: 2026-08-29T01:15:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.